Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

YKL-40 in patients with end-stage renal disease receiving haemodialysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{11c98b46bba148db8386eb0c9d1a5389,
title = "YKL-40 in patients with end-stage renal disease receiving haemodialysis",
abstract = "PURPOSE: This study aimed to determine serum YKL-40 in patients with end-stage renal disease (ESRD) on haemodialysis (HD) and to evaluate the prognostic value of serum YKL-40.METHODS: Patients >18 years on maintenance HD were included. Serum YKL-40 was measured using ELISA before and after a single HD treatment.RESULTS: A total of 306 patients were included. Median serum YKL-40 concentration was 238 µgL-1(IQR: 193-291 µgL-1) before HD treatment and 198 µgL-1(IQR: 147-258 µgL-1) after HD treatment, which corresponded to age-corrected 93th percentile in healthy subjects. All-cause mortality after 2.8 years was 35.9{\%}. Patients with serum YKL-40 in the highest quartile compared with the lowest quartile had a univariate HR of 4.0 (95{\%} CI: 2.2-7.3, p < 0.001) for all-cause mortality which decreased to 2.4 (95{\%} CI: 1.1-4.5, p = 0.01) in multivariate analysis. Time-dependent receiver operating characteristic curves showed that serum YKL-40 after HD treatment had significant higher area under the curves from 90 d (p = 0.004) and throughout the rest of the follow-up period when compared to serum YKL-40 before HD treatment.CONCLUSION: YKL-40 was highly elevated in patients with ESRD on HD, and dialysis reduced serum YKL-40 concentrations approximately one-sixth. YKL-40 measured after dialysis was independently associated with mortality in HD patients.",
keywords = "Journal Article",
author = "Nielsen, {Ture Lange} and Plesner, {Louis Lind} and Warming, {Peder Emil} and Pallisgaard, {Jannik Langtved} and Morten Dalsgaard and Morten Schou and Ulla H{\o}st and Casper Rydahl and Lisbet Brandi and Lars K{\o}ber and Johansen, {Julia Sidenius} and Jens Kastrup and Iversen, {Kasper Karmark}",
year = "2018",
doi = "10.1080/1354750X.2018.1428359",
language = "English",
volume = "23",
pages = "357--363",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Taylor & Francis",
number = "4",

}

RIS

TY - JOUR

T1 - YKL-40 in patients with end-stage renal disease receiving haemodialysis

AU - Nielsen, Ture Lange

AU - Plesner, Louis Lind

AU - Warming, Peder Emil

AU - Pallisgaard, Jannik Langtved

AU - Dalsgaard, Morten

AU - Schou, Morten

AU - Høst, Ulla

AU - Rydahl, Casper

AU - Brandi, Lisbet

AU - Køber, Lars

AU - Johansen, Julia Sidenius

AU - Kastrup, Jens

AU - Iversen, Kasper Karmark

PY - 2018

Y1 - 2018

N2 - PURPOSE: This study aimed to determine serum YKL-40 in patients with end-stage renal disease (ESRD) on haemodialysis (HD) and to evaluate the prognostic value of serum YKL-40.METHODS: Patients >18 years on maintenance HD were included. Serum YKL-40 was measured using ELISA before and after a single HD treatment.RESULTS: A total of 306 patients were included. Median serum YKL-40 concentration was 238 µgL-1(IQR: 193-291 µgL-1) before HD treatment and 198 µgL-1(IQR: 147-258 µgL-1) after HD treatment, which corresponded to age-corrected 93th percentile in healthy subjects. All-cause mortality after 2.8 years was 35.9%. Patients with serum YKL-40 in the highest quartile compared with the lowest quartile had a univariate HR of 4.0 (95% CI: 2.2-7.3, p < 0.001) for all-cause mortality which decreased to 2.4 (95% CI: 1.1-4.5, p = 0.01) in multivariate analysis. Time-dependent receiver operating characteristic curves showed that serum YKL-40 after HD treatment had significant higher area under the curves from 90 d (p = 0.004) and throughout the rest of the follow-up period when compared to serum YKL-40 before HD treatment.CONCLUSION: YKL-40 was highly elevated in patients with ESRD on HD, and dialysis reduced serum YKL-40 concentrations approximately one-sixth. YKL-40 measured after dialysis was independently associated with mortality in HD patients.

AB - PURPOSE: This study aimed to determine serum YKL-40 in patients with end-stage renal disease (ESRD) on haemodialysis (HD) and to evaluate the prognostic value of serum YKL-40.METHODS: Patients >18 years on maintenance HD were included. Serum YKL-40 was measured using ELISA before and after a single HD treatment.RESULTS: A total of 306 patients were included. Median serum YKL-40 concentration was 238 µgL-1(IQR: 193-291 µgL-1) before HD treatment and 198 µgL-1(IQR: 147-258 µgL-1) after HD treatment, which corresponded to age-corrected 93th percentile in healthy subjects. All-cause mortality after 2.8 years was 35.9%. Patients with serum YKL-40 in the highest quartile compared with the lowest quartile had a univariate HR of 4.0 (95% CI: 2.2-7.3, p < 0.001) for all-cause mortality which decreased to 2.4 (95% CI: 1.1-4.5, p = 0.01) in multivariate analysis. Time-dependent receiver operating characteristic curves showed that serum YKL-40 after HD treatment had significant higher area under the curves from 90 d (p = 0.004) and throughout the rest of the follow-up period when compared to serum YKL-40 before HD treatment.CONCLUSION: YKL-40 was highly elevated in patients with ESRD on HD, and dialysis reduced serum YKL-40 concentrations approximately one-sixth. YKL-40 measured after dialysis was independently associated with mortality in HD patients.

KW - Journal Article

U2 - 10.1080/1354750X.2018.1428359

DO - 10.1080/1354750X.2018.1428359

M3 - Journal article

VL - 23

SP - 357

EP - 363

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 4

ER -

ID: 53412829